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Abstract
Sinusoidal obstruction syndrome (SOS) is a potentially life-threatening complication of allogeneic hematopoietic stem cell
transplantation (HSCT). We assessed the proposed pediatric EBMT criteria along with the Baltimore and modified Seattle
criteria in a population-based cohort. Eighty-seven children (1.1–17.3 years) undergoing myeloablative HSCT from 2010 to
2017 were consecutively included at the Danish National Transplantation Center. In total, 39 (44.8%) patients fulfilled the
EBMT criteria and 30 patients (35%) fulfilled the criteria for severe or very severe SOS. Nine (10.3%) patients fulfilled the
modified Seattle criteria while none met the Baltimore criteria. Patients fulfilling the EBMT criteria for SOS had longer
primary admission (31 days (23–183) vs. 27 days (17–61), p= 0.001), were treated more intensively with diuretics within the
first 3 months (29 days (0–90) vs. 3.5 days (0–90), p < 0.0001), and had a longer time to stable platelet counts >50 × 109/L
(32 days (16–183) vs. 23 days (14–101), p < 0.0001). Two patients, fulfilling neither Baltimore nor Seattle criteria, but
selectively fulfilling EBMT criteria, died of treatment-related acute inflammatory complications within 1 year post-HSCT. In
conclusion, application of the pediatric EBMT diagnostic and severity criteria may be helpful in identifying patients at
increased risk of severe treatment-related complications and mortality, although with a risk of over-diagnosing SOS.
Introduction
Sinusoidal obstruction syndrome (SOS), also known as
veno-occlusive disease (VOD; hereafter referred to as SOS),
is a potentially life-threatening complication of allogeneic
hematopoietic stem cell transplantation (HSCT) [1]. The
initiating pathogenic step is damage to sinusoidal endothe-
lial cells in the hepatic acinus, initiated by toxic metabolites
of the conditioning regimen. This may lead to vascular
occlusion, capillary leakage and hepatocellular necrosis,
causing fluid overload, consumptive and transfusion-
refractory thrombocytopenia and hyperbilirubinemia [2–4].
Most cases resolve within weeks, but a variable percentage
of up to 30–60% have been reported to progress to multi-
organ dysfunction/failure (MOD/MOF) with a mortality
rate of >80% [3, 5–7].
The reported incidence of SOS in children is variable and
partly related to the diagnostic criteria applied, reportedly
ranging from 20% to 60% in high-risk populations after
allogeneic HSCT [5, 7–10]. Transplant-related risk factors
include second myeloablative transplantation, unrelated and
HLA-mismatched donor, high-dose or unfractionated total
body irradiation (TBI) and conditioning with high-dose
busulfan and cyclophosphamide [4, 9–11]. Furthermore,
acute graft-versus-host disease (GvHD) and previous
hepatic disease are risk factors [4, 10, 12]. In addition, a
number of pediatric factors such as young age and low
weight as well as certain genetic diseases are associated
with increased incidence of SOS [4, 5, 7, 9, 10, 13].
Until recently, SOS has been diagnosed using the Seattle
[14] and Baltimore [15] criteria in both children and adults,
with modification of the Seattle criteria to require a 5%
weight gain in children [5]. However, the use of similar
criteria for children and adults is challenged by age-related
differences in the clinical presentation. In 15–20% of cases,
children present with SOS later than a month after HSCT [7,
9], which is rare in adults [16], and while hyperbilir-
ubinemia is an indispensable requirement in the Baltimore
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criteria, anicteric SOS has been reported in about one-third
of children, including those experiencing severe SOS [5]. If
hyperbilirubinemia is present at an early stage, it is often
pre-existing, caused by the primary diagnosis, or it may
occur late in a severe case of SOS [7, 17, 18].
Accordingly, pediatric diagnostic criteria for SOS have
been suggested by a working group under the European
Society for Blood and Marrow Transplantation (EBMT). In
these new criteria, the time-restriction of the Seattle and
Baltimore criteria has been omitted, and hyperbilirubinemia
and weight gain are evaluated based on individual baselines,
taking pre-existing clinical conditions into account. To
avoid potentially misleading insignificant changes, weight
gain and increase in bilirubin are assessed over 3 con-
secutive days and imaging techniques for ascites and
hepatomegaly are recommended to improve sensitivity and
specificity of the criteria [7]. Finally, transfusion refractory
thrombocytopenia (RT) has been added as a criterion
(Table 2) [16, 19–21].
Clinical studies indicate that defibrotide is effective for
treatment of SOS in children [5, 6, 22, 23], especially after
early intervention [24, 25], underlining the need for early
diagnosis of SOS. Since the proposed pediatric SOS criteria
are based on expert opinion like the Seattle and Baltimore
criteria, empirical studies are needed to assess their validity
and their applicability in the clinic. The Seattle and Balti-
more criteria have a reported specificity of 95% and 89%,
respectively [14, 15], with a low sensitivity of 56% [26],
though this is mainly based on studies in adult HSCT which
cannot directly be applied to children due to differences in
clinical presentation of SOS.
The purpose of this retrospective study was to assess the
new pediatric EBMT diagnostic criteria and severity grad-
ing along with the classical Baltimore and modified Seattle
criteria in a clinical study.
Patients and methods
Study population
In this population-based study, 87 children (1–18 years of
age) undergoing allogeneic HSCT were consecutively
recruited at Copenhagen University Hospital Rigshospitalet,
Denmark, from June 2010 to December 2012 and from
March 2015 to June 2017, for studies of toxicities and
immune reconstitution as described previously [27–30].
One patient was excluded due to death from fungal infec-
tion on day +9 without signs of SOS. Written informed
consent was obtained from all included patients and/or their
legal guardians after approval by the local ethics committee
(H-1-2010-009 and H-7-2014-016). The patients were fol-
lowed for 1 year post-transplant with an average follow-up
time of 314 days (56–365). Thirteen patients did not com-
plete a full year of follow-up due to relapse (n= 6), graft
rejection (n= 4), or treatment-related death (n= 3).
The clinical characteristics are listed in Table 1. Diag-
noses were malignant (n= 51) or benign diseases (n= 36).
Donors were either matched siblings (MSD) (n= 22),
matched unrelated donors (MUD) (n= 41), mismatched
unrelated donors (MMUD) (n= 10), haploidentical (n= 6),
or umbilical cord blood (UCB) (n= 8). Stem cell sources
were bone marrow (BM) (n= 69), peripheral blood stem
cells (PBSC) (n= 10), or UCB grafts (n= 8). Conditioning
regimens were TBI-based (n= 21), busulfan-based (n=
42), or other chemotherapy-based regimens (n= 24).
Four patients (4.6%) had a baseline bilirubin above
normal range. Twenty-five patients (28.7%) had a high risk
of developing SOS due to prior HSCT, allogeneic HSCT for
leukemia beyond the second relapse, diagnoses of adreno-
leukodystrophy, osteopetrosis or macrophage activation
syndrome or conditioning with busulfan and melphalan,
while no patients presented with pre-existing liver disease
or received ozogamicin-coupled monoclonal antibodies
(gemtuzumab or ozogamicin) [5]. Defibrotide was given as
SOS-prophylaxis to certain high-risk patients by the clin-
ician in charge based on a general clinical assessment, and
most frequently after the approval in 2016.
Assessment of criteria
Clinical parameters were retrospectively registered from the
patient’s medical records for the first year following HSCT.
The applied pediatric EBMT criteria are stated in Table 2.
Some of the EBMT criteria required supplementary
specifications not detailed in the article by Corbacioglu
et al. [7]. In the present study, bilirubin was considered
increased if either above normal range for the patient's age
and sex or if higher than 4 times the baseline value, as this
combination appeared to result in a consistent assessment of
rise in bilirubin. Further, baseline bilirubin was defined as
the average of the last 2–3 values measured prior to con-
ditioning. Refractory consumptive RT was defined as the
need for otherwise unexplained platelet transfusions daily
for ≥3 days to keep platelet counts above transfusion levels
(20 × 109/L). Bilirubin and platelet counts were measured at
least once daily as a routine procedure during hospitaliza-
tion, and patients were weighed at least once daily during
the admission to monitor hydration. For patients fulfilling
EBMT criteria at more than one occasion, only data
related to the first time point of SOS were applied in this
analysis.
In this study, patients were severity graded for maximum
grade of SOS by applying the pediatric EBMT severity
grading criteria [7]. These criteria categorize SOS as mild,
moderate, severe, or very severe (grade I–IV) based on the
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extent of the following parameters: duration of persistent
RT, rise of liver biomarkers, rise and kinetics of bilirubin,
amount of ascites, and impaired coagulation as well as signs
Table 1 Patient and transplant characteristics
Patient and transplant characteristics n= 87
Males 49 (56.3%)
Age at transplantation (years), median (range)
Recipients 7.8 (1.1–17.3)
Donors 22.9 (0.0–58.4)
Disease at transplantation, no. (%)
Acute lymphoblastic leukemia 27 (31.0%)
Acute myeloid leukemia 11 (12.6%)
Myelodysplastic syndrome 5 (5.7%)
Other malignancies 8 (9.2%)
Severe aplastic anemia 7 (8.0%)
Thalassemia 3 (3.4%)
Hemophagocytic lymphohistiocytosis 2 (2.3%)
X-linked lymphoproliferative syndrome 2 (2.3%)
Pediatric immunodeficiency syndromes 12 (13.8%)
Infantile osteopetrosis 1 (1.1%)
Other benign disorders 9 (10.3%)
Donor type, no. (%)
Matched sibling donor (10/10) 22 (25.3%)
Matched unrelated donor (10/10) 41 (47.1%)
Mismatched unrelated donor (9/10) 10 (11.5%)
Umbilical cord blood (8/10) 8 (9.2%)
Haploidentical donor 6 (6.9%)
Stem cell source, no. (%)
Bone marrow 69 (79.3%)
Peripheral blood stem cells 10 (11.5%)
Umbilical cord blood 8 (9.2%)
Conditioning regime, no. (%)
TBI (1200 cGy)+VP16 or CY 17 (19.5%)
TBI (200 cGy)+ CY 4 (4.6%)
BU+ CY ±VP16 10 (11.5%)
BU+ CY+MEL 15 (17.2%)
BU+ other 17 (19.5%)
Other chemotherapy-based conditioning 24 (27.6%)
ATG as part of conditioning regimen, no. (%) 67 (77.0%)
Ciclosporin as GvHD prophylaxis, no. (%) 79 (90.8%)
HSCT no.
1 85 (97.7%)
2 2 (2.3%)
Baseline bilirubin, median (range) 5.6 (2.2–43.0)
High risk of SOS, no. (%) 25 (28.7%)
Defibrotide prophylaxis, no. (%) 5 (5.7%)
TBI total body irradiation, BU busulfan, CY cyclophosphamide, MEL
melphalan, VP16 etoposide, ATG anti-thymocyte globulin, GvHD
graft-versus-host disease, HSCT hematopoietic stem cell
transplantation
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of renal, pulmonary, or CNS organ dysfunction [7]. Of liver
transaminases, only alanine aminotransferase (ALT) was
available in all patients. International Normalized Ratio and
coagulation factors II, VII, and X (both measured with ACL
TOP), as well as need for fresh frozen plasma, were used to
evaluate impaired coagulation. Oxygen requirement and
new onset cognitive impairment were registered from
medical records to assess pulmonary and CNS dysfunction,
respectively. Due to scarce data on estimated glomerular
filtration rate (eGFR) based on EDTA clearance, eGFR
was calculated based on cystatin C (n= 31) [31] or creati-
nine (n= 8) [32]. Creatinine was measured at least daily
during hospitalization (with Cobas 8000 c702), and Cysta-
tin C was measured when indicated by the clinical condition
and at least weekly for most of the period from August 2012
(with Cobas 8000 c502).
Statistical analyses
The Mann–Whitney-U test, Wilcoxon rank sum test, or
Kruskal–Wallis rank sum test were used to calculate dif-
ferences between continuous variables. Fisher’s exact test
was used for categorical variables.
Kaplan–Meier estimates with log-rank test were applied
for overall survival, transplant-related mortality, relapse,
duration of primary admission, admission to the intensive
care unit (ICU), acute and chronic GvHD, time to neutrophil
engraftment, and time to stable platelet counts >50 × 109/L.
A two-sided p-value < 0.05 was considered statistically
significant. All statistical analyses were performed using R
statistical software version 3.4.2 (The R Foundation for
Statistical Computing, Vienna, Austria) and R studio (R
Studio, Boston, MA, USA).
Results
Incidence of SOS
Thirty-nine (44.8%) patients fulfilled the EBMT criteria,
while 9 (10.3%) patients fulfilled the modified Seattle cri-
teria. Of the patients fulfilling the Seattle criteria, 8 out of 9
also fulfilled the EBMT criteria (Fig. 1), while one patient
only fulfilled the modified Seattle criteria with upper right
quadrant pain and bilirubin ≥34 µmol/L. None of the
patients met the Baltimore criteria. Three patients were
treated with defibrotide: one fulfilling Seattle criteria, one
on suspicion of late onset SOS, and one with suspected
pulmonary VOD.
Median time to diagnosis was 6 days from HSCT (0–
54 days) with EBMT criteria, and 6 days (1–13 days) with
Seattle criteria. For the 8 patients fulfilling both Seattle
and EBMT criteria, EBMT criteria were in average
fulfilled 3 days earlier than Seattle criteria. Patients ful-
filling the EBMT criteria presented with rising bilirubin
(n= 33, 84.6%), consumptive RT (n= 31, 79.5%),
weight gain (n= 26, 66.7%), ultrasound-confirmed
hepatomegaly (n= 1, 2.6%), and ultrasound-confirmed
ascites (n= 1, 2.6%). Four patients fulfilled EBMT cri-
teria at two separate time points.
When grading the patients according to the pediatric
EBMT severity criteria, 13 (14.9%) were classified as grade
IV, 17 (19.5%) as grade III, 6 (6.9%) as grade II, and 3
(3.4%) as grade I SOS.
Patient characteristics and development of SOS
Grade III–IV SOS was associated with malignant diag-
noses and conditioning with busulfan plus cyclopho-
sphamide (p= 0.039 and p= 0.015, respectively). There
were no associations with recipient age, donor
type, stem cell source, conditioning with TBI, or baseline
levels of bilirubin (Tables 3 and 4). Patients with malig-
nant diseases received TBI-based conditioning or con-
ditioning with cyclophosphamide plus busulfan plus/
minus etoposide or melphalan more commonly than
patients with benign diseases (p < 0.0001 and p= 0.0006,
respectively).
Defibrotide (25 mg/kg/day) was given to five patients
as prophylaxis due to diagnoses with increased risk of SOS
(n= 3) or pre-existing liver disease (n= 2) with a median
length of treatment of 35 days (31–40 days). Three patients
on defibrotide prophylaxis developed grade III–IV SOS
according to EBMT criteria.
Grade IV
Fulfillment of pediatric EMBT and seatte criteria of SOS
Grade II
Pe
di
at
ric
 E
BM
T 
cr
ite
ria
Grade I
Grade 0
No SOS
Seattle criteria
SOS
High risk
Standard risk
Grade III
Fig. 1 Comparison of the diagnostic criteria for patients with high- and
standard-risk of developing SOS. A child transplanted with a mye-
loablative conditioning is considered to be in high risk of SOS in case
of second myeloablative stem cell transplant, allogeneic stem cell
transplants for leukemia >2 relapses, liver disease, history of treatment
with ozogamicin-coupled monoclonal antibodies, conditioning with
busulfan and melphalan, osteopetrosis, macrophage activating syn-
dromes or adrenoleukodystrophy [5]
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SOS and duration of primary admission
Next, we evaluated the course of HSCT in patients with
SOS defined by the EBMT criteria in comparison with
patients not fulfilling these criteria. Patients fulfilling grade
III–IV SOS had a longer duration of their primary admis-
sion (31 days (23–183) vs. 27 days (17–61), p= 0.001) than
patients without SOS. In contrast, the duration of stay in
hospital did not differ between patients with milder degrees
of SOS and patients with no SOS (Fig. 2a). The number of
patients admitted to the ICU was too low (n= 3) for
assessment of any association with the pediatric EBMT
criteria.
Use of diuretics
Patients fulfilling the pediatric EBMT SOS criteria received
diuretics for more days post-HSCT within the first 3 months
(29 days (0–90) vs. 3.5 days (0–90), p < 0.0001). These
differences were significant both for grade III–IV SOS and
grade I–II SOS compared with patients without SOS (p <
0.0001 and p= 0.0022, respectively) (Fig. 2b).
Engraftment and GvHD
Time to neutrophil engraftment did not differ between
patients with and without SOS. However, stable platelet
counts >50 × 109/L were achieved later in patients with
grade III–IV SOS compared to patients without SOS
(31 days (17–183) vs. 22 days (14–101), p= 0.0003), while
no significant difference was seen for patients with milder
SOS (Fig. 2c).
Table 3 Patient and transplant characteristics according to fulfillment
of pediatric EBMT diagnostic and severity grading criteria for SOS
Patient and transplant
characteristics
Grade 0 Grade I–II Grade
III–IV
Total number of patients,
no. (%)
48 (55.2%) 9 (10.3%) 30 (34.5%)
Males 28 (57.1%) 5 (10.2%) 16 (32.7%)
Age at transplantation (years), median (range)
Recipients 7.5 (1.1–
16.6)
3.4 (1.2–
13.4)
9.1 (1.2–
17.3)
Donors 23.1 (0.0–
58.4)
22.6 (5.5–
45.4)
20.2 (0.0–
51.4)
Disease at transplantation, no. (%)
Acute lymphoblastic
leukemia
11 (40.7%) 3 (11.1%) 13 (48.1%)
Acute myeloid leukemia 3 (27.3%) 1 (9.1%) 7 (63.6%)
Myelodysplastic
syndrome
4 (80.0%) 0 (0.0%) 1 (20.0%)
Other malignancies 5 (62.5%) 1 (12.5%) 2 (25.0%)
Severe aplastic anemia 6 (85.7%) 0 (0.0%) 1 (14.3%)
Thalassemia 3 (100.0%) 0 (0.0%) 0 (0.0%)
Hemophagocytic
lymphohistiocytosis
1 (50.0%) 0 (0.0%) 1 (50.0%)
X-linked
lymphoproliferative
syndrome
2 (100%) 0 (0.0%) 0 (0.0%)
Pediatric
immunodeficiency
syndromes
8 (66.7%) 3 (25%) 1 (8.3%)
Infantile osteopetrosis 0 (0.0%) 0 (0.0%) 1 (100.0%)
Other benign disorders 5 (55.6%) 1 (11.1%) 3 (33.3%)
Donor type, no. (%)
Matched sibling donor
(10/10)
10 (45.5%) 4 (18.2%) 8 (36.4%)
Matched unrelated donor
(10/10)
25 (61.0%) 3 (7.3%) 13 (31.7%)
Mismatched unrelated
donor (9/10)
5 (50.0%) 1 (10.0%) 4 (40.0%)
Umbilical cord blood (8/
10)
4 (50.0%) 0 (0.0%) 4 (50.0%)
Haploidentical donor 4 (66.7%) 1 (16.7%) 1 (16.7%)
Stem cell source
Bone marrow 39 (56.5%) 8 (11.6%) 22 (31.9%)
Peripheral blood stem
cells
5 (50.0%) 1 (10.0%) 4 (40.0%)
Umbilical cord blood 4 (50.0%) 0 (0.0%) 4 (50.0%)
Conditioning regime, no. (%)
TBI (1200 cGy)+VP16
or CY
10 (58.8%) 1 (5.9%) 6 (35.3%)
TBI (200 cGy)+ CY 4 (100.0%) 0 (0.0%) 0 (0.0%)
BU+ CY ±VP16 3 (30.0%) 1 (10.0%) 6 (60.0%)
BU+ CY+MEL 5 (33.3%) 2 (13.3%) 8 (53.3%)
BU+ other 8 (47.1%) 1 (5.9%) 8 (47.1%)
Table 3 (continued)
Patient and transplant
characteristics
Grade 0 Grade I–II Grade
III–IV
Other 18 (75%) 4 (16.7%) 2 (8.3%)
ATG as part of conditioning
regimen, no. (%)
40 (59.7%) 5 (7.5%) 22 (32.8%)
Ciclosporin as GvHD
prophylaxis, no. (%)
43 (54.4%) 7 (8.9%) 29 (36.7%)
HSCT, no. (%)
1st 48 (56.5%) 7 (8.2%) 30 (35.3%)
2nd 0 (0.0%) 2 (100.0%) 0 (0.0%)
Baseline bilirubin, median
(range)
5.5 (2.4–
43.0)
3.7 (2.2–
13.3)
6.0 (3.0–
17.7)
High risk of SOS, no. (%) 8 (32%) 4 (16%) 13 (52%)
Defibrotide prophylaxis, no.
(%)
2 (40.0%) 0 (0.0%) 3 (60.0%)
TBI total body irradiation, BU busulfan, CY cyclophosphamide, MEL
melphalan, VP16 etoposide, ATG anti-thymocyte globulin, GvHD
graft-versus-host disease, HSCT hematopoietic stem cell
transplantation
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No difference was observed in risk of acute (p= 0.31) or
chronic (p= 0.99) GvHD between patients fulfilling and
not fulfilling EBMT SOS criteria (results not shown).
Mortality
Seven out of 87 patients (8.0%) died within the first year
following HSCT. One of the patients transplanted for non-
malignant disorders died due to the progression of neuro-
logic manifestations of metachromatic leukodystrophy post-
HSCT. Six patients transplanted for malignant diseases
relapsed, four of these with a fatal outcome.
Two patients died in remission of treatment-related
complications, both selectively fulfilling the pediatric
EBMT criteria for very severe SOS, but neither fulfilling the
classical criteria. One of these patients died in multiorgan
failure day +111, initially dominated by liver failure, pro-
pagating to kidney failure, and respiratory insufficiency.
The second patient developed progressing liver failure and
respiratory insufficiency with signs of pulmonary hyper-
tension 4.5 months after HSCT and passed away in a con-
dition of multiorgan failure. A post-mortem lung-biopsy
showed changes indicating pulmonary VOD (Fig. 3).
This limited frequency of mortality did not allow further
statistical assessment in relation to fulfillment of EBMT
SOS criteria.
Discussion
The new diagnostic EBMT criteria for pediatric SOS were
developed in an attempt to create a more dynamic
diagnostic tool adapted to the pediatric characteristics of
SOS. Since these criteria, like Seattle and Baltimore criteria,
were developed based on expert opinion rather than clinical
data, they warrant assessment and validation in clinical
cohorts. Although retrospective in design, the overall results
of this study indicate that these new criteria could be useful
in the clinic and may help to identify patients with severe
SOS and a poor outcome that do not fulfill Seattle or Bal-
timore criteria. Accordingly, the EBMT criteria appear to
compensate for the shortcomings of Seattle and Baltimore
criteria in the pediatric setting.
The modification to more dynamic assessment of weight
gain and hyperbilirubinemia as well as the addition of the
consumptive RT criterion was the primary cause that a
larger proportion of patients in our cohort were diagnosed
with SOS using the pediatric EBMT criteria. Although most
children still developed hyperbilirubinemia during SOS, the
alteration of the essential requirement of rising bilirubin in
the EBMT criteria allowed for diagnoses of SOS in six
patients with moderate/severe SOS despite the absence of
hyperbilirubinemia.
The classical criteria restrict disease onset to 21 days
post-HSCT, despite the fact that late occurring symptoms of
SOS are frequent in children. The absence of this time
restriction in the EBMT criteria played a minor role, being
critical for only 3 patients, and fulfillment of hepatomegaly
and ascites criteria was not critical for any patient in this
study.
Potential advantages of the new pediatric EBMT criteria
are related to minimization of imprecise and partly sub-
jective clinical assessment of parameters such as pain,
ascites, and hepatomegaly. This is done with the
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Fig. 2 a Duration of primary admission after hematopoietic stem cell
transplantation according to the severity grading of SOS based on
pediatric EBMT criteria. Kaplan–Meier estimates with log-rank test for
grade 0, grade I–II, and grade III–IV SOS are shown. The p-value
indicates a significant difference between the three groups. Patients
fulfilling grade III–IV SOS had a longer duration of their primary (p=
0.001) than patients without SOS. There was no significant difference
between patients with milder degrees of SOS and patients with no
SOS. b Number of days on diuretics within the first 3 months after
HSCT for patients fulfilling grade 0, grade I–II, and grade III–IV SOS.
The p-values indicate the difference between the groups of SOS
patients and patients without SOS (using the Mann–Whitney-U test). c
Time to stable platelet counts >50 × 109/L for patients fulfilling grade
0, grade I–II, and grade III–IV SOS shown as Kaplan–Meier estimates
with log-rank test. The p-value indicates a significant difference
between the three groups. Stable platelet counts >50 × 109/L were
achieved later in patients with grade III–IV SOS compared to patients
without SOS (p= 0.0003), while no significant difference was seen for
patients with milder SOS
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implementation of imaging, potentially increasing the
reliability of the diagnosis. By applying baseline values, the
new criteria also correct for shortcomings related to indi-
vidual variations caused by pre-existing clinical conditions,
which may be more frequent in the pediatric setting (e.g.,
immunodeficiencies).
However, there remain some challenges in the clinical
implementation of the new EBMT criteria. Rising bilirubin
from a baseline value on 3 consecutive days and otherwise
unexplained weight gain on 3 consecutive days despite the
use of diuretics are not fully defined regarding magnitude of
the deviation from the normal. Further, guidelines as to
whether thrombocytopenia should be interpreted as mainly
consumptive or transfusion refractory could be more closely
defined, although the EBMT severity grading criteria indi-
cate that persistent RT >3 days is representative of moderate
SOS. In this study, we have investigated different inter-
pretations and chosen the most consistent assessment based
on our patient data. We hope this can help give perspective
and further optimize the criteria.
Application of the pediatric EBMT criteria in this study
defined a broader group of patients diagnosed with SOS
than the group defined by the Seattle criteria, though most
of these patients are still included when using the pediatric
EBMT criteria. The comparatively large number of patients
fulfilling the pediatric EBMT criteria indicates a risk of
over-diagnosis. There is, for instance, a risk that slight
increases in bilirubin may be caused by hepatotoxic side
effects of medication frequently used in the clinic, such as
antibiotics, antiviral drugs and antifungals (in particular
voriconazole [33] and carbapenems [34]). As we are the
first to assess these proposed criteria, we have only our
own numbers to consider regarding the risk of over-
diagnosis.
However, when considering treatment of SOS based on
the new EBMT criteria, we find that application of the
severity grading criteria could possibly limit the group of
patients where treatment is indicated. Overall, patients
meeting the EBMT criteria for SOS had a longer duration of
the primary admission, later occurrence of stable platelet
counts, and received diuretics for a longer period, indicating
higher morbidity. This was also the case for patients with
grade III–IV SOS, but generally not for patients with grade
I–II SOS. Importantly, application of the EBMT criteria
also identified two patients among the very severe SOS
group not identified by the Seattle criteria, who developed
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Fig. 3 Patient with EBMT verified SOS not fulfilling Seattle/Baltimore
criteria: HSCT course for an 8-year old girl with AML in second
complete remission (CR2), transplanted with bone marrow from a
matched unrelated donor after conditioning with intravenous PK-
adjusted busulfan, cyclophosphamide, and melphalan. Clinical suspi-
cion of SOS from day +5 post-HSCT due to a rise of bilirubin >34
µmol/L, however without fulfillment of other Seattle or Baltimore
criteria (weight gain below 5% and no hepatomegaly/ascites/pain). By
retrospective application of the EBMT SOS pediatric criteria, this
patient fulfilled the criteria for grade IV SOS based on rapid and high
increase in bilirubin, weight gain despite use of diuretics and unex-
plained consumptive RT. Moreover, she showed impaired coagulation
(reduced coagulation factors and increased international normalized
ratio), reduced kidney function (estimated glomerular filtration rate of
28 ml/min) and the need for continuous positive airway pressure
(CPAP) for pulmonary ventilation. Around day +144, this patient
developed rapidly rising bilirubin, UL-confirmed ascites, weight gain,
consumptive RT, highly increased liver enzymes (ALT peaking at
2820 U/L), impaired coagulation, and the need for ventilator support,
again selectively fulfilling the pediatric EBMT criteria of very severe
SOS. In parallel, this patient developed respiratory insufficiency with
pulmonary hypertension. At this stage, she was commenced on defi-
brotide, but died in multi-organ failure on day +183 post-HSCT. A
post-mortem lung-biopsy showed changes suspicious for pulmonary
VOD. The figure illustrates the various clinical parameters from day of
HSCT (day 0) until transplant-related mortality (TRM). The dotted
green line marks a weight gain of 5%. The dotted orange line marks
bilirubin at 34 µmol/L. The time points for fulfillment of pediatric
EBMT criteria are marked with black arrows
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liver insufficiency progressing to fatal multiorgan failure.
This indicates that patients fulfilling severe–very severe
SOS have significantly higher morbidity and could benefit
from earlier recognition of SOS and initiation of treatment,
while mild–moderate SOS diagnosed by the EBMT criteria
might not require treatment. The median time of diagnosis
was rather early for our patients compared to the previously
reported debut at around 2 weeks post-HSCT [7–9], how-
ever, this may be explained by our retrospective study
design allowing for strict daily assessment compared to
clinical observations.
Defibrotide was not implemented in our clinic in the
beginning of the study period. Accordingly, only a few
patients were treated with defibrotide on suspicion of SOS,
and all these retrospectively fulfilled grade III–IV SOS by
EBMT criteria. Thus, this study suggests an increased
clinical awareness of patients fulfilling severe–very severe
EBMT SOS criteria. Further optimization and adjustment of
the pediatric EBMT SOS criteria should be based on pro-
spective studies.
The main limitation of this study is the retrospective use
of the EBMT criteria. The lack of patients fulfilling Balti-
more criteria can partly be explained by improper clinical
assessment and registration of hepatomegaly and ascites
throughout this period, as well as the inaccuracy of this
clinical investigation, especially in children. In general,
there was an absence of baseline ultrasound for most of our
patients as this has not been the practice in our clinic pre-
viously. However, none of our SOS diagnoses by the
pediatric EBMT criteria were dependent on hepatomegaly/
ascites alone and thus our results should not be altered.
Further limitations are that competing conditions may be
difficult to assess retrospectively as well as clinically,
especially those that mimic SOS such as thrombotic
microangiopathy and engraftment syndrome. In addition,
the high survival rates in this study did not allow any
conclusive analysis of mortality, indicating that the pro-
posed EBMT criteria should be assessed in larger pediatric
cohorts. The low frequency of high-risk patients in our
study compared to others, as well as the limited use of TBI,
could partly account for the generally excellent outcomes
[9, 35]. However, this is difficult to assess due to variation
and inconsistency in risk assessment of SOS in the literature
as well as the specific inclusion of high-risk patients in
many studies of pediatric SOS.
In conclusion, our findings suggest that application of the
pediatric EBMT diagnostic and severity grading criteria for
SOS may be helpful in identifying patients at increased risk
of severe treatment-related complications and mortality.
However, further assessment of the EBMT criteria based on
larger prospective studies with the potential for clinical
intervention is needed.
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